Compare CMTL & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMTL | RFL |
|---|---|---|
| Founded | 1967 | 2017 |
| Country | United States | United States |
| Employees | 1385 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Real Estate |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.1M | 61.1M |
| IPO Year | 2024 | 2017 |
| Metric | CMTL | RFL |
|---|---|---|
| Price | $5.23 | $1.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 296.0K | 58.8K |
| Earning Date | 03-16-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $499,528,000.00 | $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.97 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $1.19 | $1.12 |
| 52 Week High | $6.21 | $3.19 |
| Indicator | CMTL | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 76.62 |
| Support Level | $4.86 | $1.41 |
| Resistance Level | $6.15 | $1.60 |
| Average True Range (ATR) | 0.35 | 0.07 |
| MACD | -0.10 | 0.02 |
| Stochastic Oscillator | 36.36 | 75.61 |
Comtech Telecommunications Corp is a provider of communications technology and solutions. It operates in two reportable business segments: Satellite and Space Communications and Allerium. The company's Satellite and Space Communications segment, which generates maximum revenue, is organized into four technology areas: satellite modem and amplifier technologies, troposcatter technologies, cybersecurity training, and space components. This segment designs and manufactures modems, amplifiers, traveling wave tube amplifiers, frequency converters, and offers other associated software and services. The Allerium segment provides next-generation 911 (NG-911) infrastructure and solutions for state and local governments and carriers. Geographically, the company derives its key revenue from the USA.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.